FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is a variant of nucleic acids with CpG reduced content encoding a FVIII protein and methods for the use thereof.
EFFECT: nucleic acid with CpG reduced content variants encoding FVIII are more efficiently expressed by cells, secreted at higher levels by cells than by a wild protein factor VIII, exhibit increased expression and/or activity compared to the protein factor VIII of the wild type or are more efficiently packaged in viral vectors.
105 cl, 15 dwg, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF GENOTHERAPY USING FACTOR VIII (FVIII) GENE | 2018 |
|
RU2808274C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| CODON-OPTIMIZED NUCLEIC ACID THAT ENCODES B-DOMAIN-DELETED FACTOR VIII PROTEIN AND ITS USE | 2022 |
|
RU2808564C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
